Alnylam Pharmaceuticals

Alnylam (Cambridge, MA). 2024 revenue ~$2.2B. RNAi therapeutics pioneer. Onpattro (patisiran), Givlaari (givosiran), Oxlumo (lumasiran), Amvuttra (vutrisiran). GalNAc-siRNA conjugate delivery platform.